The U.S. Food and Drug Administration on Thursday unveiled a revised regulatory framework governing nicotine pouches and next-generation vaping devices, formalising what critics describe as a significant relaxation of oversight that had been building since a restructuring of the agency's tobacco division earlier this year. The announcement follows reporting that major tobacco manufacturers, including Philip Morris International and Reynolds American, stand to benefit substantially from looser pre-market authorisation requirements for their newest product lines.

The policy shift drew immediate condemnation from global health officials attending the 79th World Health Assembly in Geneva, where WHO member states are in the final days of their annual summit. Several delegations, including representatives from the European Union, Australia, and a bloc of African nations, called on the United States to reconsider the move, arguing it undermines international commitments under the Framework Convention on Tobacco Control. WHO Director-General Dr. Tedros Adhanom Ghebreyesus said the organisation was 'deeply concerned' that reduced scrutiny of nicotine delivery products could reverse decades of progress in youth tobacco prevention.

Public health organisations in the United States were swift to respond. The American Cancer Society, the Campaign for Tobacco-Free Kids, and the American Lung Association issued a joint statement Thursday calling the FDA's new posture 'a gift to an industry that kills 480,000 Americans each year.' The groups announced they were exploring legal options to challenge the revised guidance in federal court, arguing the agency had failed to follow required notice-and-comment rulemaking procedures.

FDA Commissioner Dr. Marty Makary defended the framework in a press briefing, arguing that harm reduction principles support making lower-risk nicotine alternatives more accessible to adult smokers while maintaining prohibitions on marketing to minors. He said the agency would continue to require manufacturers to demonstrate that their products meet a 'appropriate for the protection of public health' standard, but acknowledged that the evidentiary threshold for novel non-combustible products had been recalibrated.

Market analysts noted that shares of Altria Group and Philip Morris International rose in early Thursday trading in anticipation of the announcement. The development sets up a prolonged political and legal battle heading into the summer, with several Democratic senators announcing they would seek Congressional hearings into the FDA's decision-making process and the role of industry lobbying in shaping the new rules.